Andrea Small-Howard, Phd, Mba Email and Phone Number
Andrea Small-Howard, Phd, Mba work email
- Valid
- Valid
- Valid
Andrea Small-Howard, Phd, Mba personal email
- Valid
Andrea Small-Howard, Phd, Mba phone numbers
Dr. Andrea Small-Howard has 20+ years of executive experience in the biopharma industry. She has shaped corporate strategies and messaging, led partnering efforts, and raised capital. In addition, she has supervised research & development, manufacturing, and quality control in global divisions. Dr. Small-Howard has taken novel biological products from ideation through commercialization. She has been named an inventor on seventy+ patent applications, taken the lead in obtaining regulatory approvals from the U.S. Food and Drug Administration ("US FDA"), and orchestrated commercial licensing deals.Currently, Dr. Small-Howard leverages her broad biopharmaceutical industry knowledge as the Chief Executive Officer, Chief Science Officer, and Chairman of the Board of Directors at GB Sciences, Inc. (OTCQB:GBLX), and she serves on the Board of Directors of their wholly-owned Canadian subsidiary, GBS Global Biopharma, Inc. Dr. Small-Howard is the architect of a strategic vision at Gb Sciences/GbS Global Biopharma to make safe, effective, standardized cannabinoid medicines available to patients where their use can be supported with rigorous evidence. To achieve standardization in their cannabinoid-containing, optimized therapeutic mixtures, the Company is using synthetic cannabinoids produced under current Good Manufacturing Practices (cGMP), which are identical in both structure and function to the homologous plant cannabinoids.Dr. Small-Howard envisages bringing more phytomedicines to market through GB Sciences’ innovative AI-based drug discovery engine and biopharmaceutical drug development programs for disease-specific indications. Dr. Small-Howard researched cannabinoids for over 20 years, leading a project group dedicated to the study of cannabinoids in the immune system as an NIH-funded post-doctoral fellow. In this work she published one of the earliest studies of cannabinoid impacts on pro-inflammatory immunocytes. More recently, she has contributed to published studies on consumer protection issues surrounding ‘medicinal’ Cannabis chemovars in Nevada, co-authored scholarly reviews on cannabinoids in heart disease and Parkinson’s Disease, co-authored mechanistic studies on cannabinoid and terpene regulation of ion channels, and co-authored an innovative study demonstrating the utility of nanoparticles as delivery vehicles for Cannabis-derived therapeutic compounds.
Gb Sciences, Inc
View- Website:
- gbsciences.com
- Employees:
- 22
-
Ceo And Chairman Of The BoardGb Sciences, IncLos Angeles, Ca, Us
-
Chief Executive Officer & Chairman Of The BoardGb Sciences, Inc Jul 2024 - PresentLas Vegas, Nevada, UsGB Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The "plant-inspired" active ingredients in its therapeutic mixtures are synthetic homologues that are identical to the original plant compounds but are produced under current Good Manufacturing Practices. GB Sciences' intellectual property portfolio contains 8 issued U.S. and 14 issued foreign patents, as well as 15 U.S. and 41 foreign patent-pending applications. In its drug development pipeline, GB Sciences has five preclinical phase product development programs. GB Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. GB Sciences' formulations for chronic pain are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). Recently, the company has received positive preclinical animal results supporting their novel formulations for stress and anxiety based on animal studies at the NRC. The company has also received positive preclinical proof-of-concept data supporting its complex cannabinoid mixtures for the treatment of Cytokine Release Syndrome based on preclinical studies at Michigan State University. GB Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
-
Chief Science OfficerGb Sciences, Inc Jun 2014 - PresentLas Vegas, Nevada, UsGB Sciences, Inc. (OTCQB: GBLX), through their Canadian entity, GbS Global Biopharma, Inc., is a plant-inspired biotech company developing patented formulations of plant-inspired, minimum essential mixtures for the prescription drug market.
-
Board MemberGb Sciences, Inc Jun 2014 - PresentLas Vegas, Nevada, UsGB Sciences, Inc. (OTCQB: GBLX), through their Canadian entity, GbS Global Biopharma, Inc., is a plant-inspired biotech developing plant-inspired minimal essential mixtures (MEM) for the prescription drug market.
-
PresidentGb Sciences, Inc Jun 2021 - Jul 2024Las Vegas, Nevada, UsGB Sciences, Inc. (OTCQB: GBLX) is a plant-inspired biopharma drug development company whose goal is to create patented formulations of plant-inspired, Minimal Essential Mixtures (MEM) for the prescription drug market that target a variety of medical conditions. The active ingredients in our MEM are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices (cGMP). Gb Sciences' novel drug discovery platform has yielded 6 issued US and 3 issued international patents, as well as 18 US and 40 international patent-pending applications. In our drug development pipeline, we have five preclinical stage programs, and our lead Parkinson's disease therapeutic program is being prepared for a First-in-Human clinical trial. In addition to Parkinson's disease, Gb Sciences is developing therapeutics for chronic pain, cytokine release syndrome (CRS), Mast Cell Activation Syndrome (MCAS), anxiety, depression, and heart failure. GB Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. https://gbsciences.com
-
Chief Science Officer & DirectorGbs Global Biopharma, Inc. Mar 2019 - PresentGbS Global Biopharma (GbS) Inc. is a plant-based research and biopharmaceutical development company located in Ottawa, Canada. GbS Global Biopharma's proprietary drug discovery platform generates Active Pharmaceutical Ingredient (API) mixtures for a variety of medical indications. The company currently has Rx programs in late pre-clinical and their lead program in Parkinson's disease is being advanced towards the clinic. GbS is working with time released nanoparticles and rapid dissolve technology for effective oral delivery of their formulations in the prescription drug market. -
Board MemberCenter For Healthcare Innovation Jan 2012 - Feb 2016Chicago, Illinois, UsThe Center for Healthcare Innovation is a non-profit, non-partisan, and independent organization committed to serving as a catalyst for stimulating ideas, people, companies, and institutions to collaborate and achieve excellence in healthcare innovation, particularly in the biotechnology, medical device, nanotechnology, and pharmaceutical sectors. The CHI vision is to become the world’s #1 independent thought-leadership institution and “think tank” for the global pharmaceutical and life sciences community. -
PresidentInternational Biotechnology Solutions Jul 2011 - Nov 2015International Biotechnology Solutions creates customized, cost-effective commercialization solutions for viable yet abandoned biopharma products. Based on our understanding that the paradigm by which biotechnology and pharmaceutical products reach the market has fundamentally changed, we explore new avenues to bring healthcare products to market in regions where there are unique needs. In particular, developing commercialization solutions to meet the needs of the healthcare market in the Asia-Pacific region can be more cost effective and may benefit a larger population.
-
Board MemberCeremax Investment Corporation Jun 2011 - Mar 2013The Ceremax Investment Group was established by members of the USC EMBA Class XXV to pool its financial and intellectual resources to identify investment opportunities. Ceremax will capitalize on the collective experiences and pool of contacts of its members to source, underwrite, and manage these investment opportunities. Additionally, Ceremax will provide a channel for its members to strengthen the relationships first developed in the classroom while attending USC. -
Vice President, Scientific OversightRadient Pharmaceuticals Corporation Nov 2008 - Jul 2011• Provided oversight for global product development in multiple international business divisions• Authored and/or attained 12 patents & 3 trademarks on proprietary cancer tests, cancer (gene) therapies, cosmeceuticals, and animal models• Achieved numerous regulatory approvals for cancer tests, cancer therapies, pharmaceuticals, and cosmeceutical products with US FDA, Health Canada, Korean FDA, China SFDA, Taiwanese Ministry of Health, Indian Ministry of Health• Initiated and/or nurtured 5 international, collaborative, cancer research trial programs with universities and hospitals studying colon, lung, and pancreatic cancer; as well as general cancer screening programs that yielded 7 publications supporting cancer products• Championed Elleuxe®/Goodnak® cosmeceutical line Provided oversight for formulations, safety & effectiveness testing, regulatory strategy Led branding committee and created marketing materials with external agencies Created commercialization strategy, sourced US raw materials, hired contract manufacturers• Led and participated in internal and US FDA, CDPH, CE Mark/ISO 13485, and CMDR audits• Advised CEO and CFO on Production Capacity and Supervised Quality System for ISO 13485 and cGMP compliant medical device manufacturing facility
-
Master Of Business AdmistrationUsc Marshall School Of Business Jul 2009 - May 2011Los Angeles, Ca, UsBeta Gamma Sigma International Honor Society -
Director, Research, Development, Scientific OversightAmdl, Inc. Jul 2007 - Nov 2008• Championed DR-70® colorectal cancer test that accounts for 100% of domestic sales Patented invention, performed clinical trials, obtained US FDA, KFDA, and CMDR approvals Created commercialization strategy, advised on first exclusive distribution relationships, led branding committee, created marketing materials with the marketing department • Designed commercialization strategy for in-licensed cervical cancer test, MyHPV Kit® Developed technical product file in Korea with original manufacturer, created US prototype Sourced US raw materials, hired contract manufacturers, prepared regulatory filings • Represented company and promoted cancer tests at international cancer meetings • Advised CEO on additional licensed technologies through due diligence research
-
Manager Of Research & DevelopmentAmdl, Inc. Feb 2006 - Jul 2007• Led medical device product development for colon, lung, pancreatic and general cancer tests with an annual budget of approximately $2.4 million USD• Represented company regulatory filings directly with US FDA agency• Managed intellectual property portfolio• Achieved 28% decrease in production error rate through continuous process improvement program in manufacturing
-
Research Assistant ProfessorUniversity Of Hawaii John A. Burns School Of Medicine Jun 2004 - Jan 2006Honolulu, Hawaii, UsResponsibilities: in charge of research division devoted to the study of selenoprotein biosynthesis and role of selenoproteins in protection from oxidative damage.Projects: identifying supramolecular complexes responsible for selenocysteine incorporation; demonstrating nucleo-cytoplasmic shuttling of selenium incorporation cofactors, defining the role of oxidative stress in neuronal neuropathies caused by elevated glucose levels, defining molecular responses to oxidative stress and links to oncological processes as well as protection from oxidative stress by selenoproteins. -
Postdoctoral Research FellowThe Queen'S Medical Center Sep 2001 - Jun 2004Honolulu, Hi, UsPrincipal Investigator: Helen Turner, Ph.DProjects: the effects of cannabinoids on immune cells; oncogenic signaling by cigarette smoke condensates (CSC) in human mast cells; defining the calcium store operated transcriptome in mast cells -
Graduate Researcher/Teaching AssistantUniversity Of Southern California Aug 1992 - May 1999Los Angeles, Ca, UsPerformed independent research; served as a teaching assistant in biochemistry (won teaching awards); molecular biology, and immunology. Gave guest lectures: 1) in the freshman biology class on plant physiology and 2) histology class on reproductive tissues and morphological/functional distinctions among gastrointestinal tissues. -
Research Project SupervisorOccidental College Sep 1988 - May 1991Los Angeles, Ca, UsPrincipal Investigator: John S. Stephens, Ph. DOccidental College, Los Angeles, CA 90041The overall goal of the research project was to determine if thermal warming from the hydroelectric plant in King Harbor was having an effect on the local fauna, especially as it might have an impact on reef fish. Led monthly ichthyoplankton sample collections; supervised a team of biologists identifying fauna in the plankton trawls; and prepared monthly reports. In addition, created a dichotomous taxonomic tree for identifying the common (top 95% found in our collections) types of marine fish larvae. -
Research AssistantOccidental College Aug 1987 - Aug 1988Los Angeles, Ca, UsSupervisor: Gary Jordan, M.A.Occidental College, Los Angeles, CA 90041Monitoring effects of sport fishing on fish stocks at the Salton Sea, California.
Andrea Small-Howard, Phd, Mba Skills
Andrea Small-Howard, Phd, Mba Education Details
-
Usc Marshall School Of BusinessClass Xxv -
University Of Southern CaliforniaImmunology
-
Occidental CollegePhilosophy
Frequently Asked Questions about Andrea Small-Howard, Phd, Mba
What company does Andrea Small-Howard, Phd, Mba work for?
Andrea Small-Howard, Phd, Mba works for Gb Sciences, Inc
What is Andrea Small-Howard, Phd, Mba's role at the current company?
Andrea Small-Howard, Phd, Mba's current role is CEO and Chairman of the Board.
What is Andrea Small-Howard, Phd, Mba's email address?
Andrea Small-Howard, Phd, Mba's email address is as****@****ail.com
What is Andrea Small-Howard, Phd, Mba's direct phone number?
Andrea Small-Howard, Phd, Mba's direct phone number is +180842*****
What schools did Andrea Small-Howard, Phd, Mba attend?
Andrea Small-Howard, Phd, Mba attended Usc Marshall School Of Business, University Of Southern California, Occidental College.
What skills is Andrea Small-Howard, Phd, Mba known for?
Andrea Small-Howard, Phd, Mba has skills like Biotechnology, Lifesciences, Molecular Biology, Biochemistry, Pharmaceutical Industry, Commercialization, Biopharmaceuticals, Immunology, Fda, Clinical Trials, Life Sciences, Medical Devices.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial